☰

Enara Bio

Data flow from proteomics to IND-ready evidence

Industry
Biotechnology
Headquarters
Oxford, United Kingdom
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Enara Bio's published strategy and is not endorsed by, or produced in cooperation with, Enara Bio. Company website

Strategic priorities

Enara Bio is preparing the IND submission and First-in-Human entry of ENA101 in 2026 — the first bispecific T-cell engager designed against a cancer-specific Dark Antigen called DARKFOX. The company has raised $84.1M to date across a Series A in 2021 and a $32.5M Series B in October 2024, led by M Ventures and Pfizer Ventures, with milestones of more than EUR 876M attached to its expanded January 2026 collaboration with Boehringer Ingelheim.

The company's working surface is the EDAPT discovery platform, which runs DDA-MS, PRM-MS, DIA-MS and Ribo-seq workflows on primary tumour and healthy tissue samples, and the EnTiCE protein-engineering toolkit, which refines the resulting bispecific T-cell engagers. Both sit inside the Oxford Science Park site, where planning applications have been submitted for three new laboratory and office buildings adding around 400,000 square feet to support what the company describes as a fivefold expansion in operational scale.

The data produced by EDAPT — assay runs, peptide-spectrum matches, candidate antigens — has to land in regulatory-grade evidence for the 2026 IND package. That path runs through laboratory information systems, computational biology models and the company's own Python-based bioinformatics pipelines currently hosted on DigitalOcean, and is the place where the next set of digital decisions are being made.

A leadership refresh underlines the operational intent. Stacey Davis joined as Chief Business and Financial Officer in May 2025 with a stated focus on operational excellence, and Scott Drutman, MD, PhD, joined as Chief Medical Officer in January 2026 from Volastra and Regeneron with a remit to bridge discovery and the clinic. Both roles arrive at a moment when the data and laboratory infrastructure has to match what Big Pharma partners and regulators expect to see.

Challenges we see

  • Data Integration

    Linking proteomics instruments to the validation pipeline

    The EDAPT platform runs DDA-MS, PRM-MS, DIA-MS and Ribo-seq workflows that produce the evidence behind Dark Antigen candidates such as DARKFOX. That data has to move from mass spectrometers through laboratory information systems into computational biology models and onward into IND documentation.

    Where the path from instrument to validated result is assembled by hand, the same dataset is interpreted multiple times in slightly different forms, and the time between a mass spectrometry run and a regulated deliverable lengthens with every transfer.

  • Compliance Regulatory

    Moving the laboratory from paper to ALCOA+ records

    ENA101 advances into IND-enabling studies in November 2025, and FDA and EMA audits require that discovery data meets ALCOA+ standards — Attributable, Legible, Contemporaneous, Original and Accurate. The company's published data currently includes Excel-based and paper-based laboratory records.

    Proving data integrity under audit is easier when the evidence is captured by the system that produced it than when it has to be reconstructed from notebooks and spreadsheets, and the move from paper to digital records is most useful when it happens before the inspection rather than after.

  • Operations Manufacturing

    Keeping pace with TCE format refinement

    Bispecific T-cell engagers such as ENA101 require precise control over protein folding, kinetics and binding affinities, and every EnTiCE molecular format refinement asks for a corresponding update to manufacturing protocols, safety logic and testing parameters.

    When each format change requires a manual retool of the production recipe, the time the team spends on engineering overhead grows with each candidate, which compresses the window in which a new format can be explored.

  • Digital Integration

    Making EDAPT output available to protein engineers

    Computational biology teams generate the EDAPT platform's insights, while EnTiCE scientists execute protein engineering in the laboratory. The two groups share data but typically work in different software environments.

    Where the handoff between discovery and engineering depends on exports and shared folders, the time between identifying a candidate and starting the next engineering iteration is governed by the data plumbing rather than the biology.

  • Operations Integration

    Integrating legacy equipment into the expanded Oxford site

    The 400,000 square foot Oxford Science Park expansion will introduce new laboratory and office buildings alongside the existing Magdalen Building facility, which holds established proteomics instruments, balances and chromatography units.

    Connecting instruments of different generations into one data path is more predictable when the network and equipment data contracts are agreed before procurement, and more expensive when retrofitting has to happen after commissioning.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Linking proteomics instruments to IND-ready evidence

    DDA-MS, PRM-MS, DIA-MS and Ribo-seq output sits in instrument software and laboratory notebooks, and the path to computational biology models and IND documentation passes through manual transfers that are hard to audit at the speed required for a 2026 submission.

    Connecting instruments through a documented pipeline into a shared proteomics data model lets validation evidence flow from mass spectrometer to IND report with provenance preserved, so the same dataset supports discovery decisions, partner reporting and regulatory submission.

    • Enara Bio, EDAPT platform technology page
    • Enara Bio, EnTiCE platform technology page

  2. Capturing ALCOA+ data at the bench

    Some laboratory records for ENA101's discovery work are held in spreadsheets and paper notebooks, and ALCOA+ requirements apply as soon as IND-enabling studies begin in November 2025.

    Replacing paper logbooks with electronic lab notebooks and instrument-integrated workflows means data is captured with instrument identity, method version and timestamp attached, and the audit trail follows the experiment rather than being reconstructed after it.

    • Enara Bio, ENA101 IND-enabling studies announcement, November 2025
    • FDA data integrity guidance for ALCOA+

  3. Reducing manual handling in proteomic sample workflows

    EDAPT's multi-modal validation workflow handles large numbers of samples through manual handling and visual inspection, which constrains throughput as the Oxford site scales toward fivefold.

    Vision-based sample inspection and barcode-driven sample tracking take counting and chain-of-custody work off the bench, so sample volume can grow without a proportional growth in manual effort.

    • Enara Bio, EDAPT platform technology page
    • Enara Bio, Oxford Science Park expansion plans

  4. Reconfiguring TCE workflows between Dark Antigen classes

    Bispecific T-cell engagers need different production recipes for cell-surface and HLA-presented Dark Antigen candidates, and a fixed production line means each new candidate class triggers a retool.

    Modular automation with documented equipment interfaces allows production modules to be reconfigured through recipe changes rather than hardware changes, so a new candidate class can be set up in days instead of weeks.

    • Enara Bio, EnTiCE platform technology page
    • NAMUR / VDI / VDE MTP working group, Module Type Package standard

  5. Securing partner data exchange for Boehringer Ingelheim milestones

    The expanded January 2026 Boehringer Ingelheim collaboration moves large volumes of bespoke discovery data into partner systems, and the EUR 876M milestone envelope depends on data being exchanged accurately and on time.

    An identity-based network architecture between the Oxford operational environment and partner endpoints protects Dark Antigen intellectual property during exchange, while still giving authorised Boehringer Ingelheim collaborators the access they need.

    • Enara Bio, Boehringer Ingelheim collaboration announcement, January 2026
    • Enara Bio, 2026 outlook statement

What we'd propose

  • Enterprise AI

    Shared proteomics data model for EDAPT

    We connect the EDAPT platform's mass spectrometers and laboratory systems into an ontology-based proteomics data model, so DDA-MS, PRM-MS, DIA-MS and Ribo-seq output lands in one place with provenance preserved and is available to discovery, engineering and regulatory teams.

    • Proteomics ontology and ingestion

      One agreed model for assays and results

      Define peptide, spectrum, peptide-spectrum match, run and sample as explicit entities with relationships, then load DDA-MS, PRM-MS, DIA-MS and Ribo-seq output into that model with validation at the boundary so a peptide-spectrum match recorded once is queryable everywhere.

    • Instrument and LIMS connectivity

      Connecting mass spectrometers and lab systems

      Connect mass spectrometers, chromatography systems and the laboratory information systems around them through documented protocols, so raw data leaves instruments with the metadata that gives it meaning rather than waiting for manual export.

    • Analytics and retrieval for discovery and IND

      Asking questions of the combined data

      Expose the data model through dashboards and a retrieval layer so computational biologists, protein engineers and regulatory writers can each query the same evidence without commissioning a new extract for every question.

    • The dataset produced by EDAPT is queried once and supports discovery, partner reporting and IND documentation.
    • Mass spectrometry output reaches the IND report with its provenance intact rather than after a chain of manual transfers.
    • New assays and Dark Antigen classes attach to the existing model rather than triggering a new integration project.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Electronic lab notebook and instrument-integrated workflows

    We replace paper logbooks and manual transcription with an electronic lab notebook, instrument integrations and 21 CFR Part 11 audit trails, so ALCOA+ evidence is captured as the work happens and is ready for FDA and EMA review.

    • Electronic lab notebook rollout

      Capturing records at the bench

      Roll out an electronic lab notebook configured for Enara's EDAPT and EnTiCE workflows, with experiment templates, versioned protocols and electronic signatures that satisfy 21 CFR Part 11, the US rule on electronic records and signatures.

    • Instrument integration to the ELN

      Results captured at the source

      Connect balances, plate readers and proteomics instruments so results arrive in the notebook with instrument identity, method version and timestamp attached, taking transcription out of the chain of custody.

    • Training and calibration checks before execution

      Preventive compliance at the bench

      Verify that the analyst running the protocol has current training and that the instrument has current calibration before the experiment is allowed to start, so compliance is checked in the workflow rather than after the fact.

    • Laboratory records are produced by the system that ran the experiment, with electronic signatures and an intact audit trail.
    • Compliance checks happen before the run, so an analyst without current training does not generate new data on the instrument.
    • The same digital record supports both IND documentation and inspection answers, removing the work of reconstructing evidence.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    Vision-based sample handling for EDAPT workflows

    We deploy vision-based inspection and barcode-driven sample tracking in the EDAPT workflow, so routine counting and chain-of-custody work is handled by the system and scientists can focus on the validation decisions the system cannot make.

    • Vision-based sample inspection

      Automated counting and anomaly flags

      Apply trained vision models to microscope and plate images to count cell populations and flag anomalies during the EDAPT validation workflow, so routine counting is consistent and anomalies surface in minutes rather than at the end of the run.

    • Barcode-driven sample tracking

      Chain of custody without paperwork

      Track samples through the EDAPT workflow by barcode and digital chain-of-custody records, so every step is logged automatically and the risk of mislabelling drops as sample volume grows.

    • Anomaly detection across runs

      Patterns across many runs

      Run anomaly detection across completed EDAPT runs to flag contamination signatures and process drift early, so failed experiments are caught at the point they start rather than at the point they finish.

    • Routine counting and chain-of-custody work is handled by the system, so scientists spend less time on tasks that do not require scientific judgement.
    • Sample volume can grow with the Oxford expansion without a proportional growth in manual handling effort.
    • Anomalies are visible at the point they appear, giving the team a chance to redirect the experiment before it fails.

    We've done this before

    See how we do Digital Lab
  • Digital CDMO

    Modular automation for TCE format changes

    We implement modular automation with documented equipment interfaces so the EnTiCE production line can be reconfigured between Dark Antigen candidate classes through recipe changes rather than hardware changes.

    • Module Type Package interface

      Documented equipment interfaces

      Implement the Module Type Package (MTP) interface standard so each EnTiCE workstation exposes a documented service description, allowing new equipment to be added to the line without bespoke integration work.

    • Virtual commissioning for new formats

      Recipe tested before the hardware moves

      Test new TCE production recipes in a virtual commissioning environment before they are loaded onto the physical line, so a new molecular format can be validated in software rather than through a series of wet trial runs.

    • Recipe management by configuration

      New formats through configuration

      Manage TCE production recipes as versioned configuration rather than as physical line changes, so a switch between cell-surface and HLA-presented Dark Antigen candidates is a configuration update rather than a retool.

    • Switching between Dark Antigen candidate classes becomes a configuration change rather than a hardware retool.
    • New TCE formats are validated virtually before they reach the bench, cutting engineering overhead per format change.
    • The same modular approach is reusable for other Dark Antigen candidate classes as the EDAPT platform expands.

    We've done this before

    See how we do Digital CDMO
  • Enterprise AI

    Identity-based networking for partner data exchange

    We design an identity-based network architecture between the Oxford operational environment and partner endpoints, so Boehringer Ingelheim collaborators and academic partners get the data they need while Dark Antigen intellectual property stays protected.

    • Identity-based access for partner data

      Partner access with a verified identity

      Apply identity-based access controls to the data exchange endpoints, so Boehringer Ingelheim collaborators and academic partners reach only the datasets their work requires, with every access recorded for audit.

    • Network segmentation between IT and OT

      Discovery and operations kept apart

      Segment the Oxford network between computational biology (IT) and laboratory operations (OT), so a compromised discovery workstation cannot reach the laboratory control network and laboratory data does not leak into the discovery environment.

    • Audit-logged data exchange

      Every exchange on the record

      Capture every cross-partner data exchange with a signed audit log, so milestone deliverables can be reconciled against what was sent and received, and an investigation has a starting point that does not depend on recollection.

    • Partner collaborators reach the data they need while Dark Antigen intellectual property stays inside the Oxford environment.
    • IT and OT network segments keep a discovery breach from reaching laboratory operations, and laboratory data from leaking outward.
    • Every cross-partner exchange is recorded, so milestone reporting can be reconciled against an audit trail rather than a recollection.

    We've done this before

    See how we do Enterprise AI

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Enara Bio's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 35 → 85
Proteomics output currently passes through laboratory information systems and Python-based pipelines on DigitalOcean, and the move to an ontology-based platform with automatic ingestion is still ahead of the company rather than behind it.
Regulatory compliance 30 → 90
ENA101 enters IND-enabling studies in November 2025 with some paper-based and Excel-based laboratory records, and the move to electronic records with ALCOA+ audit trails is the work that has to happen before FDA and EMA inspections.
Manufacturing modularity 25 → 75
EnTiCE workflows adjust to each molecular format refinement through manual retooling, and the move to modular automation with documented equipment interfaces is a precondition for handling multiple candidate classes in parallel.
IT/OT integration 40 → 85
Computational biology teams and laboratory scientists work in different software environments, and the move to shared data models and segmented networks is what allows the Oxford expansion to operate as one site rather than as a collection of independent groups.
Automation and AI 30 → 70
Routine counting and chain-of-custody work in EDAPT is handled by hand, and the move to vision-based inspection and barcode-driven tracking is what allows the Oxford site to scale sample volume without scaling headcount at the same rate.
Cloud and infrastructure 35 → 80
Bioinformatics workloads run on DigitalOcean with Python pipelines that have not been validated against GAMP5, and the move to a compliant, high-availability environment is a precondition for sustained collaboration with Big Pharma partners.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Enara Bio, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].